Radiation exposure is an increasing concern in medical, military and homeland security scenarios. In the medical field alone, each year 6.5 million patients globally receive radiation as a therapy for cancer. 500,000 of these cases are in the US. Although radiation is a primary method to fight cancer, radiation has multiple harmful, and currently unpreventable side effects. Two such ailments include permanent damage to salivary glands (xerostomia) and severe skin damage (radiation dermatitis). These two conditions are estimated to cost more than $3 billion per year to treat in the US alone.
BioCurity has developed a novel, platform biotechnology called Sentry that protects against and treats radiation-related xerostomia and radiation dermatitis. Sentry is delivered via injection for the xerostomia indication and has been formulated as topical ointment for the prevention of radiation dermatitis. Sentry Injectable is currently concluding pre-clinical development and is expected to begin Phase I clinical trials by Q4 2014. Sentry Topical is currently in the midst of pre-clinical development and is projected to enter Phase I clinical trials by Q3 2015. BioCurity owns the IP for the core technology and is currently pursuing additional protections in the US and abroad.